Librax Shortage: What Providers and Prescribers Need to Know in 2026

Patients on Librax (chlordiazepoxide/clidinium) are increasingly reporting difficulty filling their prescriptions at local pharmacies. While Librax is not on the FDA's current drug shortage list as of 2026, providers are fielding calls and messages from patients who cannot locate the medication. This clinical briefing summarizes what prescribers need to know about the current availability landscape, how to write prescriptions to maximize fill success, and how to manage patients who cannot locate their medication.

Current Availability Picture: What the Data Shows

As of 2026, chlordiazepoxide/clidinium is not listed on the FDA Drug Shortage Database. Multiple FDA-approved generic manufacturers — including Amneal, Nuvo, and Teva — hold approved ANDAs and continue production. Brand Librax, distributed by Bausch Health, remains approved but carries an extremely high retail price (over $3,500 per 60 capsules), making it a low-demand SKU that pharmacies rarely stock in meaningful quantity.

The clinical reality is that individual pharmacy stockouts are common and unpredictable. Librax is a low-volume medication. Pharmacies order it in small quantities, and even a brief regional wholesaler allocation gap can leave multiple pharmacies in the same area out of stock simultaneously. This is particularly problematic because abrupt discontinuation of chlordiazepoxide carries real clinical risk (see below).

Prescribing Strategies to Maximize Fill Success

Providers can take several steps at the point of prescribing to reduce the likelihood their patients will be unable to fill:

Write for generic explicitly: Write "chlordiazepoxide 5 mg / clidinium bromide 2.5 mg capsules" and ensure "dispense as written" is NOT selected. This gives the pharmacist flexibility to use any FDA-approved generic manufacturer's product, significantly broadening fill options.

Prescribe 90-day supplies where clinically appropriate: Longer fill intervals reduce how often patients must navigate pharmacy stock. Check state-specific prescribing rules, as controlled substance regulations vary.

Note the federal exemption in your prescription if needed: Librax as a combination product is federally exempt from Schedule IV under the Controlled Substances Act (21 U.S.C. § 812). Some pharmacies may be unaware of this exemption and apply additional controlled-substance handling requirements. Clarifying this can speed processing.

Consider mail-order pharmacy: Mail-order pharmacy benefit managers (PBMs) like Express Scripts and CVS Caremark typically carry broader formularies. Directing stable patients to mail-order for Librax can reduce prescription abandonment and gaps in therapy.

Clinical Risk of Abrupt Discontinuation: What Prescribers Must Know

This is the most critical clinical point. Because Librax contains chlordiazepoxide, a Schedule IV benzodiazepine, abrupt discontinuation in patients who have been on chronic therapy can precipitate serious withdrawal syndrome including:

Rebound anxiety, agitation, and irritability

Insomnia and hypersensitivity to sensory input

Tremors and muscle twitching

Seizures (in severe cases, particularly with long-term use or high doses)

When a patient cannot locate Librax, providers should have a plan ready. Do not wait for patients to experience withdrawal before acting. If bridging to another medication, a gradual taper plan should be in place before Librax supply runs out.

Clinically Appropriate Alternatives When Librax Is Unavailable

Because Librax has two active components serving distinct therapeutic functions, bridging therapy requires addressing both the antispasmodic and anxiolytic needs:

For the antispasmodic component: Dicyclomine (Bentyl) 20 mg QID or hyoscyamine (Levsin) 0.125 mg Q4H. Both are widely available generics and are not controlled substances.

For the benzodiazepine/anxiolytic component: If the patient has been on long-term Librax and has physical dependence on the chlordiazepoxide component, consider a structured taper using a longer-acting benzodiazepine under appropriate monitoring. Buspirone or an SSRI may be appropriate for the anxiety component in patients transitioning off Librax.

Donnatal: If the patient requires a combination product similar to Librax, Donnatal (phenobarbital/hyoscyamine/atropine/scopolamine) is a reasonable clinical alternative, though it is also a Schedule IV controlled substance and carries its own availability challenges.

Regulatory Considerations: Controlled Substance Status of Librax

Prescribers and staff should be aware of the somewhat unusual regulatory status of Librax. Chlordiazepoxide as a standalone drug is Schedule IV. However, the Librax combination (chlordiazepoxide + clidinium) is federally exempt from Schedule IV classification under the Controlled Substances Act when the schedule IV substance is combined with a non-controlled substance in a manner that diminishes its potential for abuse. Individual states may still regulate it more strictly — verify your state's specific requirements.

Tools to Help Your Patients Find Librax

For patients who are struggling to locate Librax, medfinder for Providers contacts pharmacies near your patient on their behalf to check which ones can fill the prescription — saving patients hours of phone calls and enabling your team to focus on clinical decisions rather than logistics. Results are sent to the patient by text.

For more on supporting patients with Librax access, see: How to Help Your Patients Find Librax In Stock: A Provider's Guide.